Bevacizumab Plus Irinotecan–Based Therapy in Metastatic Colorectal Cancer Patients Previously Treated With Oxaliplatin-Based Regimens

REFERENCES

• Cassidy, J.; Tabernero, J.; Twelves, C.; Brunet, R.; Butts, C.; Conroy, T.; Debraud, F.; Figer, A.; Grossmann, J.; Sawada, N.; Schöffski, P.; Sobrero, A.; Van Cutsem, E. Xelox (capecitabine plus oxaliplatin): activefirst-line therapy for patients with metastatic colorectalcancer. J Clin Oncol 2004, 22(11), 2084–2091.
   PubMed Web of Science ®Google Scholar
• Yaman, E.; Uner, A.; Er, O.; Coskun, U.; Buyukberber, S.; Dikilitas, M.; Polat, M.; Yamac, D.; Kaya, A.O.; Yildiz, R.; Ozturk, B.; Benekli, M. Capecitabine plusoxaliplatin (Xelox) in the treatment of chemotherapy-naivepatients with metastatic colorectal cancer. Med Oncol 2007, 24(4), 431–435. .
   PubMed Web of Science ®Google Scholar
• Goldberg, R.M.; Sargent, D.J.; Morton, R.F.; Fuchs, C.S.; Ramanathan, R.K.; Williamson, S.K.; Findlay, B.P.; Pitot, H.C.; Alberts, S. Randomized controlled trial ofreduced-dose bolus fluorouracil plus leucovorin andirinotecan or infused fluorouracil plus leucovorin andoxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. J Clin Oncol 2006, 24(21), 3347–3353.
   PubMed Web of Science ®Google Scholar
• Sørbye, H.; Glimelius, B.; Berglund, A.; Fokstuen, T.; Tveit, K.M.; Braendengen, M.; Øgreid, D.; Dahl, O. Multicenter phase II study of Nordic fluorouraciland folinic acid bolus schedule combined with oxaliplatin asfirst-line treatment of metastatic colorectal cancer. J Clin Oncol 2004, 22(1), 31–38.
   PubMed Web of Science ®Google Scholar
• Ferrara, N.; Gerber, H.P.; LeCouter, J. Thebiology of VEGF and its receptors. Nat Med 2003, 9(6), 669–676.
   PubMed Web of Science ®Google Scholar
• Kabbinavar, F.; Hurwitz, H.I.; Fehrenbacher, L.; Meropol, N.J.; Novotny, W.F.; Lieberman, G.; Griffing, S.; Bergsland, E. Phase II, randomized trial comparingbevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LValone in patients with metastatic colorectal cancer. J Clin Oncol 2003, 21(1), 60–65.
   PubMed Web of Science ®Google Scholar
• Kabbinavar, F.F.; Schulz, J.; McCleod, M.; Patel, T.; Hamm, J.T.; Hecht, J.R.; Mass, R.; Perrou, B.; Nelson, B.; Novotny, W.F. Addition of bevacizumab to bolusfluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. JClin Oncol 2005, 23(3), 3697–3705.
   PubMedGoogle Scholar
• Kabbinavar, F.F.; Hambleton, J.; Mass, R.D.; Hurwitz, H.I.; Bergsland, E.; Sarkar, S. Combined analysis ofefficacy: the addition of bevacizumab tofluorouracil/leucovorin improves survival for patients withmetastatic colorectal cancer. J Clin Oncol 2005, 23(16), 3706–3712.
   PubMed Web of Science ®Google Scholar
• Hurwitz, H.; Fehrenbacher, L.; Novotny, W.; Cartwright, T.; Hainsworth, J.; Heim, W.; Berlin, J.; Baron, A.; Griffing, S.; Holmgren, E.; Ferrara, N.; Fyfe, G.; Rogers, B.; Ross, R.; Kabbinavar, F. Bevacizumab plusirinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350(23), 2335–2342.
   PubMed Web of Science ®Google Scholar
• Fuchs, C.; Marshall, J.; Mitchell, E.; Wierzbicki, R.; Ganju, V.; Jeffery, M.; Schulz, J.; Richards, D.; Soufi-Mahjoubi, R.; Wang, B.; Barrueco, J. Randomized, controlled trial of irinotecan plus infusional, bolus, ororal fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007, 25(30), 4779–4786.
   PubMed Web of Science ®Google Scholar
• The National Comprehensive Cancer Network. Clinical practice guidelines in oncology: colon cancer, version 1. 2008. Available at http://www.nccn.org/professionals/physician_gls/PDF/colon.pdf
   Google Scholar
• Tournigand, C.; André, T.; Achille, E.; Lledo, G.; Flesh, M.; Mery-Mignard, D.; Quinaux, E.; Couteau, C.; Buyse, M.; Ganem, G.; Landi, B.; Colin, P.; Louvet, C.; de Gramont, A. FOLFIRI followed by FOLFOX6 or the reversesequence in advanced colorectal cancer: a randomized GERCORstudy. J Clin Oncol 2004, 22(2), 229–237.
   PubMed Web of Science ®Google Scholar
• Ulrich-Pur, H.; Kornek, G.V.; Fiebiger, W.; Gedlicka, C.; Raderer, M.; Lenauer, A.; Depisch, D.; Lang, F.; Pidlich, J.; Scheithauer, W. Multicenter phase II trialof dose-fractionated irinotecan in patients with advancedcolorectal cancer failing oxaliplatin-based first-linecombination chemotherapy. Ann Oncol 2001, 12(9), 1269–1272.
   PubMed Web of Science ®Google Scholar
• Stickel, F.; Jüngert, B.; Brueckl, V.; Schirner, I.; Brueckl, W.M.; Männlein, G.; Hegewald, J.; Mühldorfer, S.; Bittorf, B.; Hohenberger, W.; Hahn, E.G.; Wein, A. Weekly high-dose 5-fluorouracil as 24-h infusion andfolinic acid (AIO) plus irinotecan as second- and third-linetreatment in patients with colorectal cancer pre-treated with AIO plus oxaliplatin. Anticancer Drugs 2003, 14(9), 745–749.
   PubMed Web of Science ®Google Scholar
• Recchia, F.; Saggio, G.; Nuzzo, A.; Lalli, A.; Lullo, L.D.; Cesta, A.; Rea, S. Multicentre phase IIstudy of bifractionated CPT-11 with bimonthly leucovorin and5-fluorouracil in patients with metastatic colorectal cancerpretreated with FOLFOX. Br J Cancer 2004, 91(8), 1442–1446.
   PubMed Web of Science ®Google Scholar
• Souglakos, J.; Vardakis, N.; Androulakis, N.; Kakolyris, S.; Kouroussis, Ch.; Mavroudis, D.; Pallis, A.; Agelaki, S.; Kalbakis, K.; Georgoulias, V. Irinotecanplus weekly 5-fluorouracil and leucovorin as salvagetreatment for patients with metastatic colorectal cancer: aphase II trial. J BUON 2005, 10(1), 47–52.
   PubMedGoogle Scholar
• Mabro, M.; Artru, P.; Andre, T.; Flesch, M.; Maindrault-Goebel, F.; Landi, B.; Lledo, G.; Plantade, A.; Louvet, C.; deGramount, A. A phase II study of FOLFIRI-3(double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients. Br J Cancer 2006, 94(6), 1287–1292.
   PubMedGoogle Scholar
• Sørbye, H.; Berglund, A.; Tveit, K.M.; Ogreid, D.; Wanderås, E.H.; Wentzel-Larsen, T.; Dahl, O.; Glimelius, B. Secondary treatment and predictive factors forsecond-line chemotherapy after first-line oxaliplatin-basedtherapy in metastatic colorectal cancer. Acta Oncol 2007, 46(7), 982–988.
   PubMed Web of Science ®Google Scholar
• Giantonio, B.J.; Catalano, P.J.; Meropol, N.J.; O'Dwyer, P.J.; Mitchell, E.P.; Alberts, S.R.; Schwartz, M.A.; Benson, A.B.3rd Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treatedmetastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007, 25(12), 1539–1544.
   PubMed Web of Science ®Google Scholar
• Cohen, M.H.; Gootenberg, J.; Keegan, P.; Pazdur, R. FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist 2007, 12(3), 356–361.
   PubMed Web of Science ®Google Scholar
• Therasse, P.; Arbuck, S.G.; Eisenhauer, E.A.; Wanders, J.; Kaplan, R.S.; Rubinstein, L.; Verweij, J.; Van Glabbeke, M.; van Oosterom, A.T.; Christian, M.C.; Gwyther, S.G. New guidelines to evaluate the response totreatment in solid tumors. European Organization for Researchand Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92(3), 205–216.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute Common Toxicity Criteria (NCI-CTC) v2.0. http://ctep.info.nih.gov/reporting/ctc.html
   Google Scholar
• Kaplan, E.L.; Meier, P. Nonparametricestimation for incomplete observations. J Am Stat Assoc 1958, 53, 457–481.
   Web of Science ®Google Scholar